Catalina María Villaquirán

Caleña en Bogotá. Urológa Oncóloga. Hospital San Ignacio.

[Catalina María Villaquirán @catavt19]

@adiazhung @NorthwesternMed @amy_krambeck @MSLee_MD Teso

[European Urology Oncology @EurUrolOncol]

🌅Monday Morning Mention!

🩺Incidence of Germline Genetic Variants in Patients with a Urinary Tract Cancer and Association with Outcomes by Kent Kamau...Katharine A. Collier et al
@katecollier_md

🔎Read the full article on our website: https://t.co/6TbN2iuXU7

🙌Thank you to the authors for trusting EUO with your work!

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[European Urology Oncology @EurUrolOncol]

➡️ Now online!
https://t.co/kRwL1UOV4w

➡️ Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma by Ryan Dillon ...Florence R. Wilson et al

➡️ Thank you to the authors for trusting EUO with your work!

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[European Urology Oncology @EurUrolOncol]

Monday Morning Mention!

🩺 Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer by Quentin Josset...Stéphane Supiot et al

https://t.co/REp52mRUi2

💡 Patient summary
The OLIGOPELVIS 2–GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile.

✨ We thank the authors for trusting EUO to publish your work.

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer : TALAPRO3

https://t.co/1nldIdOdZo

In metastatic androgen pathway modulation–sensitive (APMS) #ProstateCancer with HRR gene alterations, talazoparib + enzalutamide was compared with enzalutamide alone in a phase 3, double-blind trial (~600 patients).

📊 Efficacy
At 3 years, imaging-based PFS was 77% vs 56%, translating to a 52% reduction in risk of progression or death (HR 0.48; P<0.001).
Interim OS showed a numerical trend:
• 78% vs 72% (HR 0.77; 95% CI 0.56–1.04)

⚠️ Safety
• Serious AEs: 42% vs 32%
• Grade ≥3 anemia: 51%
• Two treatment-related deaths in the talazoparib arm

💡 Take-home: Adding talazoparib significantly improves PFS in HRR-altered APMS prostate cancer, supporting earlier use of PARP inhibition, but with increased hematologic toxicity.

@neerajaiims
@AzadOncology
@quimmateo
@nealshore
@cvulsteke

@OncoAlert
@Silke_Gillessen
@AOmlin
@weoncologists

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

🚨 From #ASCO26 to NEJM 🚨
Perioperative apalutamide + ADT improves outcomes in patients with newly diagnosed high-risk localized or locally advanced #ProstateCancer in the phase 3 #PROTEUS trial.

🧑‍⚕️ 2,109 patients were randomized to receive perioperative ADT + apalutamide or placebo before and after radical prostatectomy.

Key findings:
✅ Higher pathological complete/minimal residual disease response rates (8.9% vs 1.0%)
✅ Improved 5-year metastasis-free survival (78.2% vs 73.5%)
✅ Better event-free survival
✅ Delayed need for subsequent anticancer therapy
⚠️ Grade 3–4 adverse events were more frequent with apalutamide, driven mainly by increased rash.

📖 NEJM: https://t.co/fr5uxATJcj

#ProstateCancer
@marty_gleave
@EfstathiouEleni
@DrPaulNguyen
@Albert0Briganti
@ProfHadaschik
@ashleyrossmdphd
@adamkibel_uro

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Dr Rishabh Jain @DrRishabhOnco]

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26

May 29 - June 2 | Chicago
Which trial are you watching most closely?

🌟 PLENARY GAME-CHANGERS

1️⃣ PROTEUS
Perioperative apalutamide + ADT in high-risk localized prostate cancer

2️⃣ LIBRETTO-432
Adjuvant selpercatinib in RET+ NSCLC

3️⃣ HARMONi-6
Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC

4️⃣ RASolute 302
Daraxonrasib (RMC-6236) in metastatic pancreatic cancer

5️⃣ SARC041
Abemaciclib in dedifferentiated liposarcoma

⚡ FRONTLINE & PERIOPERATIVE SHIFTS

6️⃣ KEYNOTE-B15 / EV-304
EV + pembrolizumab vs chemo in MIBC

7️⃣ LITESPARK-022
Pembrolizumab + belzutifan in adjuvant ccRCC

8️⃣ AMBITION
Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer

9️⃣ NeoADAURA
Neoadjuvant osimertinib in EGFR+ NSCLC

🔟 A-DREAM
ADT interruption strategies in mCSPC

🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY

1️⃣1️⃣ DESTINY-Breast06
T-DXd expands into HER2-ultralow disease

1️⃣2️⃣ CROWN (7-year update)
Lorlatinib durability in ALK+ NSCLC

1️⃣3️⃣ DeLLphi-312
Tarlatamab in frontline SCLC

1️⃣4️⃣ COMMIT
Atezolizumab + FOLFOX/Bev in MSI-H mCRC

1️⃣5️⃣ IMvigor011
ctDNA-guided adjuvant atezolizumab in bladder cancer

#OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @FDA approves adjuvant PD-L1 inhibitor Atezolizumab in Muscle-Invasive Bladder Cancer post surgery & ctDNA MRD (+) by @NateraGenetics Signatera CDx approved as companion diagnostic.

MRD-guided adjuvant therapy is moving into practice in Bladder Cancer!

FDA link: https://t.co/DPjLN6Ag2Z

[Julian Chavarriaga @chavarriagaj]

#AUA26 Bayesian reanalysis of 8 phase III mHSPC trials presented by Dr. Yoshida:
🔴ARASENS, PEACE-1, ARANOTE, TITAN, ENZAMET, ARCHES, STAMPEDE, and LATITUDE
⚖️ Triplet therapy (ADT + docetaxel + ARPI) vs modern doublets
📉 No clear OS advantage overall → (HR 1.04)
🎲 Probability of ANY OS benefit: 36%
🎯 Probability of clinically meaningful benefit (HR<0.8): only 11%
Signal may exist in high-volume disease… but perhaps less than many expected.
@UroToday @AmericanUrological

[European Urology Oncology @EurUrolOncol]

"Cancer of the Prostate Risk Assessment (CAPRA) score and its postsurgical variant (CAPRA-S) predict biochemical recurrence (BCR) after radical prostatectomy (RP) but do not capture tumor biology. We developed two integrated clinical scores, CAPRA-G and CAPRA-SG, combining CAPRA or CAPRA-S with Genomic Prostate Score (GPS)."

💻️ Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy by Yu Ozawa, Marcio Covas Moschovas et al

📒 Read the full article: https://t.co/xcF47WtJp8

We thank the authors for publishing their work in EUO

@Yu_pandacopanda
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[NEJM @NEJM]

Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: https://t.co/sKJ6Sr6WiW

[Jeff Ryckman @jryckman3]

1/ 🚨 New @NEJM: Perioperative enfortumab vedotin + pembrolizumab (EV+pembro) in MIBC (KEYNOTE-905)

Congrats to the authors on an important randomized phase 3 trial in a tough, cisplatin-ineligible population 👏

Let’s walk through it 👇

[Andrea Apolo, M.D. @apolo_andrea]

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

[Yüksel Ürün @DrYukselUrun]

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group @IBCG_BladderCA @EUplatinum
@shilpaonc @siadaneshmand @FaltasLab @PGrivasMDPhD @AndreaNecchi @karima_oualla @DrRosenbergMSK @UroDocAsh @Uromigos @OncoAlert @OncBrothers

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)

Full text: https://t.co/2ziB2Z24ES

@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

[European Urology Oncology @EurUrolOncol]

Now online!

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis
by Martino Pedrani et al

Read full article: https://t.co/6htV2pN5Pp

Thank you to the authors for choosing #EUO to publish your work.

@PedraniMartino
@Silke_Gillessen
@uroweb
@mroupret
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[NEJM @NEJM]

In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full phase 3 EMBARK trial results and Research Summary: https://t.co/jwAROfr840

[MEDICOS DE COLOMBIA @PROMEDICOS]

Artículo del BMJ (British Medical Journal). “Como los políticos destruyeron el sistema de salud de Colombia”

[Vive con Propósito. @PropositoyVida]

Esto es lo que provoca la gente negativa al estar cerca de los demás

[Daniel Samper Ospina @DanielSamperO]

Ahora los funcionarios de Maduro llaman a la comunidad internacional que ellos mismos despreciaron cuando se robaron las elecciones 🙄